Specialty Pharmacy

Nivolumab (Opdivo) is a PD-1 immune checkpoint inhibitor that prevents an anti-tumor immune response.

Isoform stabilizing drug may be effective targeting colitis and colon cancer.

Top news of the day from across the health care landscape.

Discovery may lead to new treatments for inflammatory bowel disease.

Women receiving radiation and chemotherapy may experience damage to their ovaries.

HIV-positive patients experience 4 times more chronic kidney disease cases than HIV-negative patients.

Treatment and cost patterns vary among psoriatic arthritis patients who switch anti-TNFα biologic therapies.

Overall and progression free survival in advanced non-small cell lung cancer improved with pembrolizumab.

Efficacy of aromatase inhibitors reduced among breast cancer patients who smoke.

Top news from around the health care landscape.

Study finds PRC2 inhibitor may treat wide range of cancer types.

Reading mammograms for longer periods of time did not reduce cancer detection, but increased overall performance.

Pharmacists can manage HIV comorbid conditions, produce cost savings, reduce drug interactions, and expedite viral load suppression.

Medication management and counseling can have a positive impact on specialty pharmacy patients.

Some types of physical activity may increase the risk of rheumatoid arthritis.

Diabetic macular oedema could be reduced by the cardiovascular drug darapladib.

Portal hypertension can result in bleeding from varicose veins in the esophagus.

Study finds risk from drinking coffee, tea, or other beverages at higher temperatures.

Gene therapy found to stop the progression of glioblastoma and high-grade glioma in mouse models.

HIV-like virus eliminated from body with early administration of treatment.

Promising new technique revealed for stopping tumor cell migration.

Top articles of the week on The American Journal of Pharmacy Benefits.

Recent advances and updates in oncology and cancer drug development.

Researchers discovered that the gene RhoC is able to control how cancer cells create energy and use glutamine.

Further research is needed for HIV to be treated by the CRISPR/Cas9 gene editing tool.

FCGR2A could indicate which patients with colorectal cancer respond to cetuximab.

Protease inhibitors can lead to the development of cardiovascular disease, diabetes, and obesity in patients with HIV.

Caregivers may have a new marker for graft-versus-host disease to monitor in transplant patients.